DMAA (Drugs Made In America Acquisition) Tariff Resilience Score: 8/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAA Drugs Made In America Acquisition Corp DMAA
14 GF Score
Price $10.70
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition Tariff Resilience Score?

Drugs Made In America Acquisition DMAA +0.09% 14 Tariff Resilience Score is 8 as of Jul. 26, 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 440 Diversified Financial Services companies, Drugs Made In America Acquisition ranks better than 99.09% on this metric.

Drugs Made In America Acquisition has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Drugs Made In America Acquisition has DMAA focuses on domestic pharmaceutical production, minimizing global supply chain dependencies. Its primary market is the U.S., reducing exposure to international tariffs. Historical data shows minimal impact from past tariffs, and the company has strong pricing power in the domestic market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Drugs Made In America Acquisition might have Highly Resilient.

Drugs Made In America Acquisition  (NAS:DMAA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Drugs Made In America Acquisition Tariff Resilience Score Related Terms

DMAA vs PLMK, TRGS, FACT: Tariff Resilience Score Comparison

For the Shell Companies subindustry, Drugs Made In America Acquisition's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drugs Made In America Acquisition Tariff Resilience Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Drugs Made In America Acquisition's Tariff Resilience Score falls into.


DMAA
14GF Score
Drugs Made In America Acquisition Corp DMAA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Drugs Made In America Acquisition (DMAA) has a Tariff Resilience Score of 8 as of Jul. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Drugs Made In America Acquisition ranks #4 out of 440 companies in the Diversified Financial Services industry, placing it in the top 0.90000000000001%.
Is Drugs Made In America Acquisition's Tariff Resilience Score too high?
Drugs Made In America Acquisition's current Tariff Resilience Score is 8. Based on the distribution chart, Drugs Made In America Acquisition ranks #4 out of 440 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's Tariff Resilience Score compare to PLMK and TRGS?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition ranks #4 out of 440 companies for Tariff Resilience Score. This places Drugs Made In America Acquisition in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Diversified Financial Services company?
A good Tariff Resilience Score depends on the Diversified Financial Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Drugs Made In America Acquisition's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current Tariff Resilience Score is 8 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition Corp is a blank check company.
14GF Score

Get the complete analysis for DMAA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.70
Price